Benign Prostatic Hyperplasia
📧 Sign up to get email alerts when something new happens for Benign Prostatic Hyperplasia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-11-30Clinical Trial Update: Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH) [NA]
This clinical trial update indicates that the Prostatic Artery Embolization (PAE) study for Benign Prostatic Hyperplasia has completed, with…
-
FDA approval · 2023-11-02FDA Approved: TAMSULOSIN HYDROCHLORIDE — Supplemental Application (EXELAN PHARMACEUTICALS, INC.)
The FDA approved a supplemental application for tamsulosin hydrochloride (Exelan Pharmaceuticals), granting approval for changes described i…
-
CLINICAL_TRIALS trial_result · 2023-11-01Clinical Trial Update: Evaluation of Symptom-specific Goal Achievement [Phase 4]
Phase 4 clinical trial evaluating symptom-specific goal achievement in benign prostatic hyperplasia and lower urinary tract symptoms has com…
-
FDA approval · 2023-10-10FDA Approved: DUTASTERIDE — Supplemental Application (XLCare Pharmaceuticals, Inc.)
The FDA approved a supplemental application for dutasteride filed by XLCare Pharmaceuticals, Inc., resulting in updated labeling.
-
FDA approval · 2023-10-10FDA Approved: FINASTERIDE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for finasteride submitted by Ascend Laboratories, LLC, resulting in an approved change to the produc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-09-26FDA Approved: DOXAZOSIN — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for doxazosin from Accord Healthcare Inc., indicating an update to the approved generic product unde…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia [Phase 3]
Phase 3 trial updates the efficacy and safety of DKF-313 in patients with benign prostatic hyperplasia.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP [Phase 3]
Phase 3 trial update evaluating intra-operative loop diuretics to improve same-day discharge after HoLEP for benign prostatic hyperplasia wi…
-
FDA approval · 2023-07-25FDA Approved: TAMSULOSIN HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved Amneal Pharmaceuticals of New York LLC's supplemental application for tamsulosin hydrochloride (generic), confirming approval o…
-
CLINICAL_TRIALS trial_result · 2023-07-14Clinical Trial Update: Adding Desmopressin to Tamsulosin for Treatment of BPH [Phase 4]
A Phase 4 clinical trial update exploring adding desmopressin to tamsulosin for nocturnal polyuria in patients with benign prostatic hyperpl…
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter [Phase 2]
Phase 2 results update for Optilume, a drug-coated balloon dilation catheter used to treat benign prostatic hyperplasia (BPH).
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II [NA]
Completed clinical trial evaluating waterjet ablation therapy for endoscopic resection of prostate tissue in BPH; results posted.
-
FDA approval · 2023-06-07FDA Approved: TAMSULOSIN HYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for tamsulosin hydrochloride submitted by Macleods Pharmaceuticals Limited.
-
FDA approval · 2023-04-26FDA Approved: DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE — Supplemental Application (Endo USA, Inc.)
The FDA approved a supplemental application for Dutasteride and Tamsulosin Hydrochloride from Endo USA, Inc., approving the combination prod…
-
FDA approval · 2023-04-26FDA Approved: DUTASTERIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for dutasteride from Aurobindo Pharma Limited under ANDA 202660.
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH [Phase 4]
Phase 4 clinical trial comparing medication to prostatic urethral lift for benign prostatic hyperplasia (BPH) to assess and compare therapie…
-
FDA approval · 2023-04-24FDA Approved: TADALAFIL — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for tadalafil filed by Camber Pharmaceuticals, Inc. This action grants an updated approval related t…
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study [Phase 4]
Phase 4 clinical trial comparing tamsulosin and tadalafil for long-term management of benign prostatic hyperplasia has completed.
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres [NA]
A completed clinical trial evaluating prostatic artery embolization (PAE) with Bead Block Microspheres for signs and symptoms of benign pros…
-
CLINICAL_TRIALS trial_result · 2023-04-07Clinical Trial Update: Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP) [Phase 4]
A Phase 4 clinical trial evaluating whether tranexamic acid improves same-day discharge rates after Holmium laser enucleation of the prostat…
-
FDA approval · 2023-01-27FDA Approved: TADALAFIL — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for tadalafil filed by Solco Healthcare US, LLC.
-
FDA approval · 2023-01-23FDA Approved: FINASTERIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for finasteride from Aurobindo Pharma Limited, granting approval for a generic finasteride product u…
-
FDA approval · 2023-01-20FDA Approved: FINASTERIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved Accord Healthcare's supplemental application for Finasteride, granting a supplemental approval under the ANDA for this product.
-
FDA approval · 2023-01-17FDA Approved: FINASTERIDE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for finasteride submitted by Ascend Laboratories, LLC.
-
FDA approval · 2022-12-16FDA Approved: TADALAFIL — Supplemental Application (AvKARE)
FDA supplemental approval for tadalafil from AvKARE (ANDA210608).